Loading...
XNAS
NVCR
Market cap1.66bUSD
Oct 08, Last price  
14.22USD
1D
-3.00%
1Q
-12.76%
Jan 2017
81.15%
IPO
-23.92%
Name

Novocure Ltd

Chart & performance

D1W1MN
XNAS:NVCR chart
P/E
—
P/S
2.53
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.47%
Rev. gr., 5y
5.80%
Revenues
655m
+8.28%
10,359,00015,490,00033,087,00082,888,000177,026,000248,069,000351,318,000494,366,000535,031,000537,840,000509,338,000605,220,000655,353,000
Net income
-136m
L-19.21%
-77,370,000-80,682,000-111,581,000-131,845,000-61,662,000-63,559,000-7,230,00019,808,000-58,351,000-92,534,000-207,043,000-168,627,000-136,227,000
CFO
-49m
L+85.94%
-52,717,000-74,244,000-99,884,000-107,592,000-33,134,000-1,865,00026,620,00099,148,00082,756,00030,788,000-73,336,000-26,369,000-49,031,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Key people

William F. Doyle
Executive Chairman of the Board · since 2016
Kinyip Gabriel Leung
Vice Chairman of the Board
Wilhelmus Groenhuysen
Chief Financial Officer · since 2012
Pritesh Shah
Chief Commercial Officer · since 2018
Asaf Danziger
President, Chief Executive Officer, Director · since 2012
Jeryl Hilleman
Independent Director · since 2018
Kinyip Leung
Independent Director · since 2020
Martin Madden
Independent Director · since 2017
Sherilyn Mccoy
Independent Director · since 2018
William A. Vernon
Lead Independent Director · since 2016
URL
https://www.novocure.com/
IPO date
Oct 01, 2015
Employees
1,320
Domiciled in
JE
Incorporated in
JE
Headquarters & legal address
2ND FLOOR, 4 THE FORUM
GRENVILLE STREET
ST HELIER JE2 4UF
JE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT